The current status of the MASHA setup
HYPERFINE INTERACTIONS
Authors: Vedeneev, V. Yu.; Rodin, A. M.; Krupa, L.; Belozerov, A. V.; Chernysheva, E. V.; Dmitriev, S. N.; Gulyaev, A. V.; Gulyaeva, A. V.; Kamas, D.; Kliman, J.; Komarov, A. B.; Motycak, S.; Novoselov, A. S.; Salamatin, V. S.; Stepantsov, S. V.; Podshibyakin, A. V.; Yukhimchuk, S. A.; Granja, C.; Pospisil, S.
Abstract
The MASHA setup designed as the mass-separator with the resolving power of about 1700, which allows mass identification of superheavy nuclides is described. The setup uses solid ISOL (Isotope Separation On-Line) method. In the present article the upgrade of some parts of MASHA are described: target box (rotating target + hot catcher), ion source based on electron cyclotron resonance, data acquisition, beam diagnostics and control systems. The upgrade is undertaken in order to increase the total separation efficiency, reduce the separation time, of the installation and working stability and make possible continuous measurements at high beam currents. Ion source efficiency was measured in autonomous regime with using calibrated gas leaks of Kr and Xe injected directly to ion source. Some results of the first experiments for production of radon isotopes using the multi-nucleon transfer reaction Ca-48+Pu-242 are described in the present article. The using of TIMEPIX detector with MASHA setup for neutron-rich Rn isotopes identification is also described.
Prediction of extravesical disease by preoperative serum markers in patients with clinically organ confined invasive bladder cancer
JOURNAL OF UROLOGY
Authors: Margel, D; Tal, R; Neuman, A; Konichezky, M; Sella, A; Baniel, J
Abstract
Purpose: We assessed the value of preoperative levels of CEA, CA-125 or CA 19-9 in patients with clinically organ confined bladder cancer to predict pathological extravesical and/or node positive disease. Materials and Methods: Serum levels of CEA, CA-125 and CA 19-9 were measured prospectively in all patients scheduled for cystectomy for clinically organ confined bladder cancer between September 1999 and May 2004. Biomarker expression was compared between patients with pathologically organ confined disease (pT2 or less, pN0) and patients with extravesical disease (greater than pT2, or pN1 or greater), and between patients with pathologically node negative (any pT, pN0) and node positive disease (any pT, pN1 or greater). Results: Of the 91 patients enrolled, 46 had (51%) pathologically organ confined tumors, 45 (49%) had extravesical disease and 17 (19%) had positive lymph nodes. Preoperative serum levels of all markers were significantly higher in cases of extravesical disease than in organ confined disease. On multivariate analysis CEA with an odds ratio of 8.6 (95% CI 1.51-48.6) and CA-125 with an OR of 29.5 (95% CI 3.6-242.6) proved independent predictors of extravesical disease. CA-125 and CA 19-9 levels were significantly higher in patients with node positive disease than in those with node negative disease. On multivariate analysis CA-125 with an OR of 22.2 (95% CI 3.8-129) and CA 19-9 with an OR of 5.2 (95% CI 1.09-24.76) proved independent predictors of node positive disease. Conclusions: Increase in serum tumor markers before cystectomy in patients with clinically organ confined muscle invasive bladder cancer is a strong indicator of the presence of extravesical and node positive disease.
COA
Publication 
Loading ......
